0001415889-24-023073.txt : 20240909 0001415889-24-023073.hdr.sgml : 20240909 20240909164704 ACCESSION NUMBER: 0001415889-24-023073 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240830 FILED AS OF DATE: 20240909 DATE AS OF CHANGE: 20240909 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gonzales Roy CENTRAL INDEX KEY: 0002035970 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40928 FILM NUMBER: 241287768 MAIL ADDRESS: STREET 1: C/O VENTYX BIOSCIENCES, INC. STREET 2: 12790 EL CAMINO REAL, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ventyx Biosciences, Inc. CENTRAL INDEX KEY: 0001851194 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 832996852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12790 EL CAMINO REAL, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 945-2393 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 3 1 form3-09092024_080900.xml X0206 3 2024-08-30 0 0001851194 Ventyx Biosciences, Inc. VTYX 0002035970 Gonzales Roy C/O VENTYX BIOSCIENCES, INC. 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130 false true false false Senior VP, Finance Common Stock 743 D Stock Option (Right to Buy) 2.14 2033-12-18 Common Stock 37500 D Stock Option (Right to Buy) 2.49 2034-01-02 Common Stock 35000 D Stock Option (Right to Buy) 33.84 2033-01-17 Common Stock 70000 D Stock Option (Right to Buy) 4.67 2034-04-09 Common Stock 12500 D One forty-eighth (1/48th) of the total shares subject to the Option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the in the Issuer's 2021 Equity Incentive Plan, the "Plan") through each such date. The Vesting Commencement Date is December 18, 2023. 100% of the total shares subject to the Option shall vest on the one-year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through such date. The Vesting Commencement Date is January 2, 2024. Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the total shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through each such date. The Vesting Commencement Date is January 9, 2023. One forty-eighth (1/48th) of the total shares subject to the Option shall vest each month on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through each such date. The Vesting Commencement Date is April 1, 2024. /s/ Austin Rutherford, as Attorney-in-Fact 2024-09-09 EX-24 2 ex24-09092024_080901.htm ex24-09092024_080901.htm

POWER OF ATTORNEY


Know all by these presents, that the undersigned hereby constitutes and appoints each of Austin Rutherford, Martin J. Waters, Robert L. Wernli, Jr., and Brandon Shaw, or either of them acting singly, and with full power of substitution and re-substitution, the undersigned’s true and lawful attorney-in-fact (each of such persons and their substitutes being referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to:

1. Prepare, execute and submit to the Securities and Exchange Commission ("SEC"), Ventyx Biosciences, Inc. (the “Company”), and/or any national securities exchange on which the Company’s securities are listed any and all reports (including any amendments thereto) the undersigned is required to file with the SEC, or which the Attorney- in-Fact considers it advisable to file with the SEC, under Section 13 or Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act") or any rule or regulation thereunder, or under Rule 144 under the Securities Act of 1933 (“Rule 144”), with respect to the any security of the Company, including Forms 3, 4 and 5, Schedules 13D and 13G, and Forms 144; and

2. Obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's equity securities from any third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact.

The undersigned acknowledges that:

a) This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information;

b) Any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable;

c) Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements of Section 13 or Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and

d) This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 13 or Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G or Forms 144 with respect to the undersigned's holdings of and transactions in securities of the Company, unless earlier revoked by the undersigned in a



signed writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all previous powers of attorney with respect to the subject matter of this Power of Attorney.


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed on August 28, 2024.



Signature:  /s/ Roy Gonzales


Print Name:   Roy Gonzales